Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2022 · 10-Q
Revenue$3.74M$3.74M−35.1% vs Q2 2021 Net Income-$100.00K-$100.00KN/M vs Q2 2021 EPS Diluted-$0.04-$0.04N/M vs Q2 2021 Gross Profit$1,241,000−50.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,304,000N/M Free Cash Flowderived-$1,329,000N/M Margins · derivedGross margin33.1%−10.2 pt vs Q2 2021
Operating margin-25.7%−28.7 pt vs Q2 2021
Net margin-2.7%−4.8 pt vs Q2 2021
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end